chloroquine has been researched along with ribavirin in 49 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (10.20) | 29.6817 |
| 2010's | 17 (34.69) | 24.3611 |
| 2020's | 27 (55.10) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Balzarini, J; Bharatam, PV; Chibale, K; Kaur, H; Little, S; Singh, K | 1 |
| Balzarini, J; Chibale, K; Kaur, H; Singh, K | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Keller, PA; Mahalingam, S; Rashad, AA | 1 |
| Balzarini, J; Chibale, K; de Kock, C; Kaur, H; Singh, K; Smith, PJ | 1 |
| Behnam, MA; Boldescu, V; Klein, CD; Nitsche, C | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Batta, G; Borbás, A; Csávás, M; Herczegh, P; Kelemen, V; Le Thai, S; Naesens, L; Rőth, E; Stevaert, A; Szűcs, Z; Vanderlinden, E | 1 |
| Bernatchez, JA; Li, J; Li, R; Luan, Y; Siqueira-Neto, JL; Tran, LT | 1 |
| Camarasa, MJ; Cumella, J; de Castro, S; Gago, F; Ginex, T; Laporte, M; Luque, FJ; Naesens, L; Stevaert, A; Vanderlinden, E; Velazquez, S | 1 |
| Agard, DA; Ashworth, A; Barrio-Hernandez, I; Batra, J; Beltrao, P; Bennett, MJ; Bohn, M; Bouhaddou, M; Braberg, H; Broadhurst, DJ; Cai, Y; Cakir, M; Calviello, L; Cavero, DA; Chang, JCJ; Chorba, JS; Craik, CS; d'Enfert, C; Dai, SA; Eckhardt, M; Emerman, M; Fabius, JM; Fletcher, SJ; Floor, SN; Foussard, H; Frankel, AD; Fraser, JS; Fujimori, DG; Ganesan, SJ; García-Sastre, A; Gordon, DE; Gross, JD; Guo, JZ; Haas, K; Haas, P; Hernandez-Armenta, C; Hiatt, J; Huang, XP; Hubert, M; Hüttenhain, R; Ideker, T; Jacobson, M; Jang, GM; Jura, N; Kaake, RM; Kim, M; Kirby, IT; Klippsten, S; Koh, C; Kortemme, T; Krogan, NJ; Kuzuoglu-Ozturk, D; Li, Q; Liboy-Lugo, J; Lin, Y; Liu, X; Liu, Y; Lou, K; Lyu, J; Mac Kain, A; Malik, HS; Mathy, CJP; McGregor, MJ; Melnyk, JE; Memon, D; Meyer, B; Miorin, L; Modak, M; Moreno, E; Mukherjee, S; Naing, ZZC; Noack, J; O'Meara, MJ; O'Neal, MC; Obernier, K; Ott, M; Peng, S; Perica, T; Pilla, KB; Polacco, BJ; Rakesh, R; Rathore, U; Rezelj, VV; Richards, AL; Roesch, F; Rosenberg, OS; Rosenthal, SB; Roth, BL; Roth, TL; Ruggero, D; Safari, M; Sali, A; Saltzberg, DJ; Savar, NS; Schwartz, O; Sharp, PP; Shen, W; Shengjuler, D; Shi, Y; Shoichet, BK; Shokat, KM; Soucheray, M; Stroud, RM; Subramanian, A; Swaney, DL; Taunton, J; Tran, QD; Trenker, R; Tummino, TA; Tutuncuoglu, B; Ugur, FS; Vallet, T; Venkataramanan, S; Verba, KA; Verdin, E; Vignuzzi, M; von Zastrow, M; Wang, HY; Wankowicz, SA; Wenzell, NA; White, KM; Xu, J; Young, JM; Zhang, Z; Zhou, Y | 1 |
| Chen, J; Chen, W; Choudhry, N; Xu, D; Yang, Z; Zanin, M; Zhao, X | 1 |
| Easwaran, M; Manickam, M; Pillaiyar, T; Wendt, LL | 1 |
| Charrel, RN; de Lamballerie, X; Ninove, L | 1 |
| Freiberg, AN; Holbrook, MR; Lee, B; Worthy, MN | 1 |
| Burt, FJ; Heise, MT; Mahalingam, S; Rolph, MS; Rulli, NE | 1 |
| Emonet, S; Ferraris, O; Ferrier Rembert, A; Moroso, M; Paranhos-Baccalà, G; Pernet, O; Peyrefitte, CN | 1 |
| Agarwal, A; Dash, PK; Gopalan, N; Joshi, G; Parida, MM; Saha, A; Sharma, S; Sukumaran, D | 1 |
| Desforges, M; Liu, G; Shen, L; Talbot, PJ; Tan, W; Yang, Y; Ye, F | 1 |
| Bhagyawant, SS; Dash, PK; Parida, M; Saha, A | 1 |
| Wang, Y; Zhu, LQ | 1 |
| Dai, Y; Huang, S; Zhang, C; Zheng, F | 1 |
| Barlow, A; Barlow, B; Claassen, CW; Heavner, JJ; Heavner, MS; Landolf, KM; Yeung, SYA | 1 |
| Cutrell, JB; Jodlowski, TZ; Monogue, ML; Sanders, JM | 1 |
| Chen, CP; Cheng, CY; Cheng, SH; Lee, YL; Liao, CH; Lin, YC; Liu, CE | 1 |
| Chen, K; Couban, RJ; Du, X; Gong, X; Guyatt, G; He, N; Ibrahim, QI; Li, X; Li, Y; Liu, F; Liu, J; Liu, W; Shen, N; Tang, Q; Wu, Z; Xu, X; Ye, Z; Ying, Y; Zhai, S; Zhang, Q; Zhang, Y; Zhou, P | 1 |
| Amore, A; Bimonte, S; Cascella, M; Celentano, E; Crispo, A; Cuomo, A | 1 |
| Almasri, H; Ata, F; Sajid, J; Yousaf, Z | 1 |
| Chen, D; Dong, L; Pan, X; Peng, C; Yang, L | 1 |
| Carvalho Junior, RN; J C Neto, AM; Martins, AY; Reis, AF; S Costa, JF; Silva Arouche, TD | 1 |
| Cameli, M; Cameli, P; Franchi, F; Mandoli, GE; Menci, D; Mondillo, S; Sciaccaluga, C; Sisti, N; Valente, S | 1 |
| Baroutjian, A; Boneva, D; Elkbuli, A; McKenney, M; Sanchez, C | 1 |
| Albreem, MA; Alomari, OA; Alsharif, MH; Alsharif, YH; Hossain, MS; Jahid, A; Solyman, AAA; Yahya, K | 1 |
| Chen, X; Huang, Z; Kuang, Y; Liu, C; Liu, P; Pan, P; Yin, M | 1 |
| Govil, A; Luckett, K; Miller-Handley, H | 1 |
| Asvadi-Kermani, T; Entezari-Maleki, T; Nouri-Vaskeh, M; Pourkarim, F; Pourtaghi-Anvarian, S; Rezaee, H | 1 |
| Wen, S; Xu, X; Yadav, AK; Yu, L | 1 |
| Danduga, RCSR; James, RA; Kandaswamy, DK; Raj, CTD; Rajasabapathy, R | 1 |
| Anedda, L; Bianchini, L; Cuzzolin, L; Fanos, V; Finco, G; Marcialis, MA | 1 |
| Libre, C; Oleinikov, A; Rahman, F; Tcherniuk, S | 1 |
| Assis, LC; da Cunha, EFF; de Almeida La Porta, F; de Castro Ramalho, T; de Castro, AA; de Jesus, JPA; Kuca, K; Nepovimova, E | 1 |
| Fernando, D; Herath, T; Rajapakse, S; Rodrigo, C; Wickramarachchi, U | 1 |
23 review(s) available for chloroquine and ribavirin
| Article | Year |
|---|---|
The Medicinal Chemistry of Dengue Virus.
Topics: Antiviral Agents; Chemistry, Pharmaceutical; Dengue; Dengue Virus; Humans; Molecular Conformation; Structure-Activity Relationship | 2016 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Drugs for the Treatment of Zika Virus Infection.
Topics: Animals; Antiviral Agents; Drug Development; Drug Discovery; Humans; Viral Vaccines; Zika Virus; Zika Virus Infection | 2020 |
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Antiviral Agents; China; Coronavirus Protease Inhibitors; COVID-19; COVID-19 Drug Treatment; Drugs, Chinese Herbal; Humans; Medicine, Chinese Traditional; SARS-CoV-2; Small Molecule Libraries | 2020 |
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
Topics: Antiviral Agents; Chemistry, Pharmaceutical; COVID-19; Disease Outbreaks; Drug Repositioning; Humans; Virus Internalization | 2021 |
Antiviral treatment of chikungunya virus infection.
Topics: Alphavirus Infections; Antiviral Agents; Chikungunya virus; Chloroquine; Humans; Interferons; Ribavirin; RNA, Viral | 2009 |
Chikungunya: a re-emerging virus.
Topics: Aedes; Africa; Alphavirus Infections; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Viral; Antiviral Agents; Arthralgia; Asia; Chikungunya Fever; Chikungunya virus; Chloroquine; Communicable Diseases, Emerging; Disease Outbreaks; Europe; Humans; Indian Ocean Islands; Insect Vectors; Ribavirin; Viral Vaccines | 2012 |
Pharmaceutical care recommendations for antiviral treatments in children with coronavirus disease 2019.
Topics: Adolescent; Age Factors; Antiviral Agents; Child; Child, Preschool; China; Chloroquine; Coronavirus Infections; COVID-19; Female; Humans; Indoles; Infant; Infant, Newborn; Interferon-alpha; Lopinavir; Male; Pandemics; Pharmaceutical Services; Pneumonia, Viral; Practice Guidelines as Topic; Prognosis; Ribavirin; Risk Assessment; Severe Acute Respiratory Syndrome; Treatment Outcome | 2020 |
Controversial treatments: An updated understanding of the coronavirus disease 2019.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Extracorporeal Membrane Oxygenation; Glucocorticoids; Humans; Liver, Artificial; Ribavirin | 2020 |
Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azetidines; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Immunomodulation; Interferon-alpha; Lopinavir; Nelfinavir; Nitro Compounds; Pandemics; Pneumonia, Viral; Purines; Pyrazoles; Ribavirin; Ritonavir; SARS-CoV-2; Sulfonamides; Thiazoles | 2020 |
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Immunoglobulins; Immunologic Factors; Indoles; Lopinavir; Oseltamivir; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2; Withholding Treatment | 2020 |
Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis.
Topics: Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Evidence-Based Medicine; Humans; Hydroxychloroquine; Indoles; Influenza, Human; Lopinavir; Observational Studies as Topic; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2 | 2020 |
Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
Topics: Adenosine Monophosphate; Alanine; Animals; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Drug Combinations; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Drugs, Investigational; Humans; Indoles; Lopinavir; Multicenter Studies as Topic; Neuraminidase; Pandemics; Pneumonia, Viral; Primates; Ribavirin; Ritonavir; SARS-CoV-2; Treatment Outcome | 2020 |
Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; China; Chloroquine; Coronavirus Infections; COVID-19; Drug Combinations; Drugs, Chinese Herbal; Humans; Indoles; Interferons; Lopinavir; Lung; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2; Survival Analysis | 2020 |
COVID-19 and the burning issue of drug interaction: never forget the ECG.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antiviral Agents; Arrhythmias, Cardiac; Chloroquine; COVID-19 Drug Treatment; Drug Combinations; Drug Interactions; Electrocardiography; Heart Failure; Humans; Hydroxychloroquine; Hypoxia; Inflammation; Long QT Syndrome; Lopinavir; Myocarditis; Myocardium; Precipitating Factors; Receptors, Interleukin-6; Respiratory Distress Syndrome; Ribavirin; Ritonavir; SARS-CoV-2; Water-Electrolyte Imbalance | 2021 |
SARS-CoV-2 pharmacologic therapies and their safety/effectiveness according to level of evidence.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Dexamethasone; Drug Combinations; Evidence-Based Medicine; Humans; Hydroxychloroquine; Interferon beta-1b; Lopinavir; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Ribavirin; Ritonavir; Systematic Reviews as Topic | 2020 |
Application of machine intelligence technology in the detection of vaccines and medicines for SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Artificial Intelligence; Ascorbic Acid; Chloroquine; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Deep Learning; Drug Combinations; Drug Development; Drug Repositioning; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lopinavir; Machine Learning; Ribavirin; Ritonavir; Vitamins | 2020 |
Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function.
Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; COVID-19 Vaccines; Creatinine; Cytidine; Dexamethasone; Drug Combinations; Drug Interactions; Humans; Hydroxychloroquine; Hydroxylamines; Immunization, Passive; Interferons; Janus Kinase Inhibitors; Lopinavir; Pyrazines; Renal Elimination; Renal Insufficiency, Chronic; Renal Replacement Therapy; Ribavirin; Ritonavir; SARS-CoV-2 | 2020 |
Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Drug Interactions; Humans; Lopinavir; Ribavirin; Ritonavir; SARS-CoV-2 | 2021 |
Antiviral treatment in COVID-19: which is the most promising?-a narrative review.
Topics: Adenosine Monophosphate; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azetidines; Chloroquine; COVID-19; COVID-19 Serotherapy; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Interferons; Ivermectin; Lopinavir; Nitro Compounds; Oseltamivir; Purines; Pyrazines; Pyrazoles; Ribavirin; Ritonavir; Sulfonamides; Thiazoles | 2021 |
COVID-19: molecular pathophysiology, genetic evolution and prospective therapeutics-a review.
Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Serotherapy; Dexamethasone; Drug Repositioning; Evolution, Molecular; Humans; Hydroxychloroquine; Immunization, Passive; Lopinavir; Pandemics; Phylogeny; Prospective Studies; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2 | 2021 |
What if COVID-19 affects the child: which weapons and how to use them.
Topics: Adenosine Monophosphate; Adolescent; Age Factors; Alanine; Antibodies, Monoclonal, Humanized; Anticoagulants; Antiviral Agents; Carrier State; Child; Child, Preschool; Chloroquine; Continuous Renal Replacement Therapy; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Drug Combinations; Extracorporeal Membrane Oxygenation; Glucocorticoids; Humans; Hydroxychloroquine; Immunization, Passive; Immunoglobulins, Intravenous; Immunologic Factors; Infant; Infant, Newborn; Interferon-alpha; Lopinavir; Oseltamivir; Receptors, Cell Surface; Respiration, Artificial; Ribavirin; Ritonavir; SARS-CoV-2; Severity of Illness Index; Thrombosis | 2021 |
Treatment of chikungunya-associated joint pain: a systematic review of controlled clinical trials.
Topics: Anti-Inflammatory Agents; Arthralgia; Chikungunya Fever; Chloroquine; Humans; Hydroxychloroquine; Methotrexate; Observational Studies as Topic; Retrospective Studies; Ribavirin | 2022 |
1 trial(s) available for chloroquine and ribavirin
| Article | Year |
|---|---|
Safety and Efficacy of Ixekizumab and Antiviral Treatment for Patients with COVID-19: A structured summary of a study protocol for a Pilot Randomized Controlled Trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antimalarials; Antiviral Agents; Case-Control Studies; China; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Humans; Indoles; Interleukin-17; Lopinavir; Middle Aged; Ribavirin; Ritonavir; Safety; SARS-CoV-2; Th17 Cells; Treatment Outcome | 2020 |
25 other study(ies) available for chloroquine and ribavirin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
Topics: Aminoquinolines; Animals; Antimalarials; Cell Line; DNA; Dogs; Heme; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Plasmodium falciparum; Protoporphyrins; Pyrimidines; Structure-Activity Relationship; Viruses | 2012 |
Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies.
Topics: Antimalarials; Antiviral Agents; Cell Line; Chemistry Techniques, Synthetic; DNA; Heme; Humans; Plasmodium falciparum; Pyrimidines; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Chikungunya virus: emerging targets and new opportunities for medicinal chemistry.
Topics: Alphavirus Infections; Chikungunya Fever; Chikungunya virus; Disease Outbreaks; Europe; Humans; Models, Molecular | 2014 |
Synthesis, antiplasmodial activity and mechanistic studies of pyrimidine-5-carbonitrile and quinoline hybrids.
Topics: Animals; Antimalarials; Antiviral Agents; Cell Line; DNA Viruses; Dose-Response Relationship, Drug; Heme; Humans; Mice; Models, Molecular; Molecular Structure; Nitriles; Parasitic Sensitivity Tests; Plasmodium falciparum; Pyrimidines; Quinolines; RNA Viruses; Structure-Activity Relationship | 2015 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
Topics: Antiviral Agents; Cell Line; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Humans; Influenza A virus; Influenza B virus; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship; Teicoplanin | 2018 |
N-benzyl 4,4-disubstituted piperidines as a potent class of influenza H1N1 virus inhibitors showing a novel mechanism of hemagglutinin fusion peptide interaction.
Topics: Animals; Antiviral Agents; Dogs; Dose-Response Relationship, Drug; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A Virus, H1N1 Subtype; Madin Darby Canine Kidney Cells; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Piperidines; Structure-Activity Relationship | 2020 |
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Evaluation, Preclinical; Drug Repositioning; HEK293 Cells; Host-Pathogen Interactions; Humans; Immunity, Innate; Mass Spectrometry; Molecular Targeted Therapy; Pandemics; Pneumonia, Viral; Protein Binding; Protein Biosynthesis; Protein Domains; Protein Interaction Mapping; Protein Interaction Maps; Receptors, sigma; SARS-CoV-2; SKP Cullin F-Box Protein Ligases; Vero Cells; Viral Proteins | 2020 |
Combined chloroquine and ribavirin treatment does not prevent death in a hamster model of Nipah and Hendra virus infection.
Topics: Animals; Antiviral Agents; Chloroquine; Cricetinae; Disease Models, Animal; Drug Therapy, Combination; Hendra Virus; Henipavirus Infections; Humans; Mesocricetus; Nipah Virus; Ribavirin; Survival Analysis; Treatment Outcome | 2010 |
Evaluation of Crimean-Congo hemorrhagic fever virus in vitro inhibition by chloroquine and chlorpromazine, two FDA approved molecules.
Topics: Animals; Antiviral Agents; Cell Line; Chloroquine; Chlorpromazine; Drug Repositioning; Drug Synergism; Hemorrhagic Fever Virus, Crimean-Congo; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Ribavirin; Virus Internalization | 2015 |
Development of a SYBR green I-based quantitative RT-PCR for Ross River virus: Application in vector competence studies and antiviral drug evaluation.
Topics: Aedes; Alphavirus Infections; Animals; Antimalarials; Antiviral Agents; Benzothiazoles; Chlorocebus aethiops; Chloroquine; Diamines; Humans; Insect Vectors; Microbial Sensitivity Tests; Organic Chemicals; Quinolines; Real-Time Polymerase Chain Reaction; Ribavirin; RNA, Viral; Ross River virus; Saliva; Vero Cells | 2016 |
Safe and Sensitive Antiviral Screening Platform Based on Recombinant Human Coronavirus OC43 Expressing the Luciferase Reporter Gene.
Topics: Antiviral Agents; Cell Line; Chloroquine; Coronavirus Infections; Coronavirus OC43, Human; Genes, Reporter; HEK293 Cells; Humans; Luciferases; Respiratory Tract Infections; Ribavirin; Virus Replication | 2016 |
Vector-delivered artificial miRNA effectively inhibited replication of Chikungunya virus.
Topics: Animals; Antimalarials; Antiviral Agents; Chikungunya virus; Chlorocebus aethiops; Chloroquine; DNA Replication; Genetic Vectors; MicroRNAs; Ribavirin; RNA Interference; Transfection; Vero Cells; Viral Plaque Assay; Virus Replication | 2016 |
Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan.
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Combinations; Female; Humans; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Ribavirin; Ritonavir; SARS-CoV-2; Taiwan; Virus Shedding | 2020 |
COVID-19 presenting with diarrhoea and hyponatraemia.
Topics: Abdominal Pain; Adult; Antimalarials; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Darunavir; Diagnosis, Differential; Diarrhea; Humans; Hyponatremia; Male; Pandemics; Pneumonia, Viral; Ribavirin; SARS-CoV-2; Treatment Outcome | 2020 |
Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with Fragment Molecular of the COVID-19 Main Protease with Inhibitor N3 Complex (PDB ID:6LU7) Using Molecular Docking.
Topics: Adenine; Adenosine; Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Binding Sites; Chloroquine; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cysteine Endopeptidases; Drug Interactions; Humans; Hydrogen Bonding; Hydroxychloroquine; Ligands; Molecular Docking Simulation; Nanotechnology; Pandemics; Pneumonia, Viral; Protease Inhibitors; Pyrazines; Pyrrolidines; Ribavirin; SARS-CoV-2; Static Electricity; Viral Nonstructural Proteins | 2020 |
Chloroquine and pyrimethamine inhibit the replication of human respiratory syncytial virus A.
Topics: Animals; Antiviral Agents; Cell Line; Cell Survival; Chloroquine; Disease Models, Animal; Female; Humans; Immunocompromised Host; Mice; Mice, Inbred BALB C; Pyrimethamine; Respiratory Syncytial Virus Infections; Respiratory Syncytial Virus, Human; Ribavirin; Virus Replication | 2021 |
Effect of drug metabolism in the treatment of SARS-CoV-2 from an entirely computational perspective.
Topics: Adenine; Adenosine; Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Design; Drug Discovery; Humans; Metabolic Networks and Pathways; Molecular Docking Simulation; Nitro Compounds; Pyrazines; Pyrrolidines; Ribavirin; SARS-CoV-2; Thiazoles | 2021 |